Drug Profile
Imiglucerase - Sanofi
Alternative Names: Cerecyme; Cerezyme; GZ 437843; ImigluceraseLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Genzyme Corporation
- Developer Sanofi
- Class Glucosidases
- Mechanism of Action Glucosylceramidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Gaucher's disease; Gaucher's disease type III
- Phase III Gaucher's disease type I
Most Recent Events
- 02 Jan 2023 Imiglucerase is still in phase III trials for Gaucher's disease type I in Argentina, Canada, France, Italy, Japan, Russian, Spain, Sweden, Turkey, Netherlands, United Kingdom
- 02 Jan 2023 Imiglucerase is still in phase III trials for Gaucher's disease type III in Argentina, Canada, France, Italy, Japan, Russian, Spain, Sweden, Turkey, Netherlands, United Kingdom
- 01 Dec 2020 Launched for Gaucher's disease type III (In adolescents, In children, In the elderly, In adults) in China (IV) (NCT04656600)